NPS+ (¹Ì±¹) - Á¶Çöº´
NPS+ (US) - Schizophrenia
»óǰÄÚµå : 1789649
¸®¼­Ä¡»ç : FirstWord Group
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 8,000 £Ü 11,235,000
Multi User License (PDF) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀÌ º¸°í¼­´Â Á¤½ÅºÐ¿­Áõ Ä¡·á ºÐ¾ß¿¡¼­ ºê·£µå ¼º°ú¸¦ ¼øÃßõÁö¼ö(NPS)¿Í ÀÇ»çµéÀÌ º¸°íÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ Á¶»çÇß½À´Ï´Ù. ºê·£µå °ÇÀü¼º, Ãæ¼ºµµ, ó¹æ ÇàŸ¦ »ó¼¼ÇÏ°Ô Æò°¡Çϰí, ÀÇ»çµéÀÌ ÁÖ¿ä ºê·£µå¸¦ ¾î¶»°Ô ÀνÄÇϰí ÀÖ´ÂÁö, ¹«¾ùÀÌ ±×µéÀÇ ¼±Åÿ¡ ¿µÇâÀ» ¹ÌÄ¡´ÂÁö ¹àÇô³»°í ÀÖ½À´Ï´Ù. NPS º¥Ä¡¸¶Å©¿Í ´õºÒ¾î ºê·£µå ¸Þ½ÃÁöÀÇ °ø¸íµµ, ºê·£µå ÁöÁöÀÚ¿Í ÀÌÅ»ÀÚÀÇ ÀÎ½Ä Â÷ÀÌ, ºê·£µå°¡ Àüȯ¿¡ ¿µÇâÀ» ¹Þ±â ½¬¿î ºÐ¾ß¿¡ ´ëÇØ¼­µµ °ËÁõÇϰí ÀÖ½À´Ï´Ù. °ËÁõµÈ ÀÇ»çµé·ÎºÎÅÍ ¼öÁýÇÑ Á¤·®Àû µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î Çϸç, ÀÌ Ä¡·á ¿µ¿ª¿¡¼­ °æÀï»çÀÇ Æ÷Áö¼Å´×°ú ¼ºÀå °¡´É¼ºÀ» µ¥ÀÌÅÍ¿¡ ±â¹ÝÇÏ¿© º¸¿©ÁÝ´Ï´Ù.

ÁÖ¿ä Áú¹®

ÁÖ¿ä ºê·£µå

  • Abilify(aripiprazole)
  • Abilify Asimtufii(aripiprazole)
  • Abilify Maintena(aripiprazole)
  • Caplyta(lumateperone)
  • Clozaril(clozapine)
  • Cobenfy(trospium chloride/xanomeline)
  • Invega(paliperidone)
  • Invega Sustenna(paliperidone palmitate)
  • Latuda(lurasidone)
  • Lybalvi(olanzapine/samidorphan)
  • Risperdal(risperidone)
  • Vraylar(cariprazine)
  • Zyprexa(olanzapine)

Á¶»ç¹æ¹ý

FirstView º¸°í¼­´Â 300¸¸ ¸í ÀÌ»óÀÇ Àǻ簡 È®ÀÎµÈ ¼¼°è ÃÖ´ë ÀÇ»ç µð·ºÅ丮ÀÎ LiMATMÀ» ÅëÇØ ¼±º°µÈ ÀÇ»çµéÀ» ´ë»óÀ¸·Î ½Ç½ÃÇÑ Á¤·®Àû ¼³¹®Á¶»ç¸¦ ÅëÇØ °³¹ßµÇ¾ú½À´Ï´Ù. °¢ ÀÇ»ç´Â ¾ö°ÝÇÑ ½É»ç ±âÁØ¿¡ µû¶ó ½ÅÁßÇÏ°Ô ¼±Á¤µÇ¾î ¼öÁýµÈ ÀλçÀÌÆ®°¡ ÀûÀýÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖÀ¸¸ç, ÃÖ°í ¼öÁØÀÇ ÀÇ·á Àü¹®°¡ÀÇ Áø½É°ú °æÇèÀ» ¹Ý¿µÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. Á¶»ç °á°ú´Â ÇØ¼®Çϱ⠽¬¿î ±×·¡ÇÁ·Î Ç¥½ÃµÇ¾î µ¥ÀÌÅ͸¦ ºü¸£°Ô ÆÄ¾ÇÇÏ°í ºÐ¼®ÇÒ ¼ö ÀÖ½À´Ï´Ù. FirstView º¸°í¼­´Â LiMATMÀÇ ¹æ´ëÇÑ µµ´Þ ¹üÀ§¿Í Á¤È®¼ºÀ» Ȱ¿ëÇÏ¿© Àü·«Àû °èȹ ¼ö¸³À» À§ÇÑ Å¹¿ùÇÑ µ¥ÀÌÅͺ£À̽º ÀλçÀÌÆ®¸¦ Á¦°øÇÔÀ¸·Î½á ºü¸£°Ô º¯È­ÇÏ´Â ÇコÄɾî ȯ°æ¿¡¼­ ÇÑ ¹ß ¾Õ¼­ ³ª°¥ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

¿ì¸® º¸°í¼­ÀÇ Æ¯Â¡Àº ¹«¾ùÀΰ¡?

FirstWord Reports´Â Á¦¾à ºÎ¹®¿¡ ƯȭµÈ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¾÷°è ¸®´õ·Î¼­ ¹ÙÀÌ¿À Á¦¾à Àü¹®°¡¿Í ÀÇ»ç°áÁ¤±ÇÀÚ¸¦ À§ÇÑ »ó¼¼ÇÏ°í ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ´ç»çÀÇ ½ÉÃþÀûÀÎ ¾÷°è Áö½ÄÀº °í°´ÀÌ »õ·Î¿î µ¿ÇâÀ» ÆÄ¾ÇÇÏ°í º¹ÀâÇÑ ¹®Á¦¸¦ È¿°úÀûÀ¸·Î ÇØ°áÇÒ ¼ö ÀÖµµ·Ï ÀûÀýÇÏ°í °¡Ä¡ ÀÖ´Â ÀλçÀÌÆ®¸¦ Á¦°øÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ±¤¹üÀ§ÇÑ Á¶»ç¿Í ÃÖ°í ¼öÁØÀÇ Àü¹®°¡ ¹× KOLÀÇ µ¶¸³ÀûÀÌ°í °øÁ¤ÇÑ ÀλçÀÌÆ®¸¦ ¹ÙÅÁÀ¸·Î ÇÑ ´ç»çÀÇ º¸°í¼­´Â °í°´ÀÌ ÇÊ¿ä·Î ÇÏ´Â Á¤È®¼º°ú ½Å·Ú¼ºÀ» Á¦°øÇÕ´Ï´Ù. ´Ù¸¥ °÷¿¡¼­´Â ¾òÀ» ¼ö ¾ø´Â ÀÎÅͺä¿Í µ¥ÀÌÅÍ¿¡ ´ëÇÑ µ¶Á¡Àû Á¢±Ù, Áö¼ÓÀûÀÎ ½ÃÀå ¸ð´ÏÅ͸µÀ» ÅëÇØ ½ÃÀå ¿ªÇÐÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. 40 ÀÌ»óÀÇ KOL ÀλçÀÌÆ®¿Í Á¤·®Àû ÀÇ»ç Á¶»ç¸¦ Æ÷ÇÔÇÑ ÀÇ»ç ÀÎÅÚ¸®Àü½º, ±×¸®°í ÀÇ·á ¹®Á¦, µðÁöÅÐ Çコ, ¿µ¾÷ ¹× ¸¶ÄÉÆÃ, ½ÃÀå Á¢±Ù ¹× ±âŸ ºÐ¾ßÀÇ À̽´¿¡ ´ëÇÑ ¾÷°è Àü¹®°¡µéÀÇ °ßÇØ¸¦ Á¦°øÇÏ´Â ´ç»çÀÇ º¸°í¼­´Â º¸´Ù ½º¸¶Æ®ÇÏ°í µ¥ÀÌÅͺ£À̽ºÀÇ ÀÇ»ç°áÁ¤À» ³»¸®°í ±Þº¯ÇÏ´Â ¾÷°è¿¡¼­ °æÀï·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

This report explores brand performance in the schizophrenia treatment landscape through the lens of Net Promoter Score (NPS) and physician-reported insights. It provides a detailed assessment of brand health, loyalty, and prescribing behavior, highlighting how physicians perceive leading brands and what influences their choices. In addition to NPS benchmarks, the report examines brand messaging resonance, differences in perception between Promoters and Detractors, and areas where brands may be vulnerable to switching. Findings are based on quantitative data collected from verified physicians and offer a data-driven view of competitive positioning and growth potential in this therapeutic area.

Key Questions Answered:

Key Brands:

  • Abilify (aripiprazole)
  • Abilify Asimtufii (aripiprazole)
  • Abilify Maintena (aripiprazole)
  • Caplyta (lumateperone)
  • Clozaril (clozapine)
  • Cobenfy (trospium chloride/xanomeline)
  • Invega (paliperidone)
  • Invega Sustenna (paliperidone palmitate)
  • Latuda (lurasidone)
  • Lybalvi (olanzapine/samidorphan)
  • Risperdal (risperidone)
  • Vraylar (cariprazine)
  • Zyprexa (olanzapine)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â